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PHeart Rhythm Disorders
Reduced Atrial Tachyarrhythmia Susceptibility
After Upgrade of Conventional Implanted
Pulse Generator to Cardiac Resynchronization
Therapy in Patients With Heart Failure
Demetris Yannopoulos, MD,* Keith G. Lurie, MD, FACC,*† Scott Sakaguchi, MD, FACC, FHRS,*†
Simon Milstein, MD, FACC,† Cengiz Ermis, MD,* Laura VanHeel, RN,†
David G. Benditt, MD, FACC, FRCPC, FHRS*†
Minneapolis and St. Cloud, Minnesota
Objectives We sought to identify the impact of cardiac resynchronization therapy (CRT) on atrial tachyarrhythmia (AT) susceptibil-
ity in patients with left ventricular (LV) systolic dysfunction in whom worsening heart failure (HF) resulted in upgrade
from conventional dual-chamber pulse generator to cardiac resynchronization therapy-defibrillator (CRT-D).
Background Cardiac resynchronization therapy with a defibrillator improves survival rates and symptoms in patients with LV
systolic dysfunction but little is known about its effects on AT incidence in the same patient population.
Methods Twenty-eight consecutive HF patients who underwent device upgrade to CRT-D were included. Patients had 2
device interrogations in the 1 year before upgrade and 3 interrogations in the 18- to 24-month follow-up after
upgrade. Echocardiographic parameters were assessed before and at 3 to 6 months after CRT-D. Additional ob-
servations included number of hospital stays, HF clinical status, and concomitant pharmacological therapy. By
virtue of this study design, each patient served as his/her own control. Statistical analysis was performed by
2-tailed paired t test and with nonparametric tests where appropriate.
Results Within 3 months after CRT, the number of HF patients with documented AT decreased significantly from the immedi-
ate pre-CRT value and tended to decline with time. At 1-year follow-up, 90% of patients were AT-free compared with
14% of patients 3 months before CRT (p 0.001). Furthermore, the number of AT episodes/year and their maxi-
mum duration decreased after CRT (mean SD; 181  50 vs. 50  20.2, p  0.05, and 220.8  87 s vs. 28 
21 s, p  0.05, respectively). Finally, CRT was associated with improved LV ejection fraction (mean SD; from 26 
5.3% to 31  7%, p  0.001) and reduced number of HF or arrhythmia hospital stays (p 0.05).
Conclusions Our findings support the view that CRT might decrease AT susceptibility in HF patients with LV systolic
dysfunction. (J Am Coll Cardiol 2007;50:1246–51) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.096d
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wardiac resynchronization therapy (CRT) has been shown
o improve both mortality and morbidity in patients with
oderate to severe systolic heart failure (HF) associated
ith ventricular dyssynchrony (1–4). Additionally, in some
ut not all reports, CRT has also been associated with
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007, accepted April 24, 2007.iminished susceptibility to ventricular tachyarrhythmias in
F patients (5–8).
See page 1252
Improvement of left ventricular (LV) function, mitral
egurgitation severity, and neurohormonal balance is
hought to be the basis for CRT benefit in HF patients (3).
iven these desirable CRT effects, it is reasonable to
nticipate that atrial function would be similarly benefited.
owever, to date, the reported impact of CRT on atrial
achyarrhythmia (AT) susceptibility in HF has varied
9,10). Thus, Hoppe et al. (9) reported no apparent benefit,
hereas Fung et al. (10) observed diminished AT suscep-ibility in CRT-treated patients.
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September 25, 2007:1246–51 CRT Impact on Atrial TachyarrhythmiasThis study re-examined the potential for CRT to dimin-
sh frequency and duration of documented AT episodes in
atients with symptoms of worsening HF due to diminished
V systolic function. However, only patients undergoing
upgrade” of a conventional dual-chamber implantable
acemaker or cardioverter-defibrillator (ICD) system to a
ardiac resynchronization therapy-defibrillator (CRT-D) sys-
em were included. This study design had 2 principal advan-
ages. First, because implantable devices were present in all
atients throughout the study period, characterization of AT
vents was as complete as possible both before and after CRT.
econd, each patient served as his/her own control.
ethods
atient population. The study population comprised a
onsecutive series of 28 patients 18 years of age who
nderwent successful upgrade from a conventional dual-
hamber pacemaker or ICD to a biventricular ICD
CRT-D) at either the University of Minnesota Medical
enter, Minneapolis, or Central Minnesota Heart Center,
t. Cloud, Minnesota. All patients had moderate to severe
ongestive HF associated with diminished LV systolic
unction and had a dual-chamber pacemaker or dual-
hamber ICD implanted for 1 year before upgrade to a
RT-D.
mplantation technique. Pulse generator and pacing elec-
rode placement used standard transvenous implantation
echniques. In the case of CRT-D implantation, details
ave been previously published (8). Devices were pro-
rammed to assure biventricular pacing for as much time as
ossible. Initial programming was DDDR mode with a
ase-rate of 70 beats/min.
Devices from 3 major U.S. manufacturers were used (St.
ude Medical Inc., Guidant Corp., and Medtronic Inc.).
he same manufacturer was used before and after upgrade
n all cases to maintain consistency of AT detection criteria.
ndications for upgrade, inclusion/exclusion criteria. The
ecision for upgrade to CRT-D was based on clinical
udgment when there was a need, despite aggressive medical
herapy, to address worsening HF as indicated by 1 or more of:
Increasing frequency of HF hospital stays
Deteriorating exertional tolerance or development of HF
symptoms at rest
Clinical signs of increasing pulmonary congestion and/or
peripheral edema
n addition to the clinical indications for CRT upgrade just
escribed, study inclusion criteria included:
QRS duration 120 ms. No echocardiographic criteria
of mechanical dyssynchrony were used.
The presence, before CRT “upgrade,” of a full-featured
conventional dual-chamber pulse generator (pacemaker
or ICD) capable of recording and storing occurrence,
duration, and cycle length of high-rate atrial events. •Successful placement of a
complete CRT-D system by
transvenous technique.
At least 2 pulse generator in-
terrogations each year before
upgrade and every-3-month
interrogations within the 18
to 24 months after upgrade.
A minimum follow-up of 2
years, including 1 year be-
fore and 18 to 24 months after
CRT upgrade.
tudy exclusion criteria were the
resence of any of the following:
Inability of implanted device to provide atrial data as
defined earlier
Permanent atrial fibrillation
Incomplete follow-up
he AT episodes were defined as all high-rate atrial events
ocumented by the implanted pulse generator. After CRT,
igh-rate atrial episodes were assessed prospectively for up
o 2 years. All patients were alive at last follow-up. No
atient was lost to follow-up. All patients underwent
chocardiographic assessment of LV systolic function
ithin 3 months before and 3 to 6 months after CRT-D
mplantation.
Before initiation of CRT therapy, no patient was exposed
o prolonged periods of right ventricular apex pacing. The
ercent ventricular paced cardiac cycles obtained at the most
ecent device interrogation before CRT “upgrade” was
15%. Device follow-up confirmed biventricular pacing
85% (range 85% to 100%) of the time, subsequent to
nitiation of CRT.
ollow-up procedures. Study patients underwent pulse
enerator interrogation at a minimum every 3 months but
ere also seen and device interrogation was undertaken at
ntervening times as circumstances dictated. Clinical data
ollected at each visit included:
Number and nature of intervening hospital stays or
illness, if any
HF clinical status
Current pharmacological therapy
ll pulse generators permitted full disclosure of AT events
ith date, duration, and cycle length. However, owing to
emory limitations, intracardiac electrograms were not
vailable for all events. Those that were available were
xamined to assess the regularity of atrial cycle lengths (Fig.
). Arrhythmia data recorded at each clinic visit included:
Number of AT episodes
Longest and shortest duration of recorded episodes
Abbreviations
and Acronyms
AT  atrial tachyarrhythmia
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization
therapy-defibrillator
HF  heart failure
LV  left ventricular
LVEF  left ventricular
ejection fractionHighest atrial rates recorded by the devices
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CRT Impact on Atrial Tachyarrhythmias September 25, 2007:1246–51efinitions. Atrial tachyarrhythmias were defined as ex-
ended episodes (5 beats) of atrial rates 180 beats/min.
hen intra-atrial electrograms showed an irregularly irreg-
lar atrial rate 180/min, atrial fibrillation was diagnosed.
owever, because electrograms were available in only a
inority (approximately 40%) of episodes, the more general
erm “AT” was used. The AT burden was determined from
he total number and duration of documented high-rate
trial events and is presented on a per-month basis.
tatistical analysis. Nonparametric tests (Wilcoxon
atched-pairs signed ranks, exact McNemar’s and Fried-
an’s tests) were used to analyze differences in medications,
ercent of patients with ATs, number of episodes/month
nd hospital stays before and after CRT upgrade due to
bsence of normal distributions. A paired t test was used for
he analysis of QRS duration and echocardiographic param-
ters due to normal distribution. A p value of 0.05 was
onsidered statistically significant.
esults
linical findings. The initial implanted device was a dual-
hamber pacemaker in 3 (10%) patients, whereas the re-
aining 25 (90%) patients had had an implanted dual-
hamber ICD. Baseline clinical and demographic data are
rovided in Table 1. During 2-year follow-up there were no
hanges in the comorbid conditions associated with HF and
o significant change in pharmacological therapy (Table 2).
Baseline and post-CRT echocardiographic findings and
RS duration are summarized in Table 1, and medications
re summarized in Table 2. Upgrade to CRT resulted in a
ignificant improvement of LV ejection fraction (LVEF)
rom 26 5.3% to 31 7.0%, p 0.05. Left atrial size and
stimated severity of mitral regurgitation were not signifi-
antly altered.
rrhythmia observations. At 1 year before CRT upgrade,
5% of patients exhibited AT episodes documented by
Figure 1 Intracardiac Electrogram of Atrial Fibrillation
Intracardiac atrial and ventricular electrograms during atrial tachyarrhythmia episod
before cardiac resynchronization therapy. Atrio-atrial (A-A) and ventriculo-ventricularevice interrogation (Fig. 2). At 3 months before upgrade,
c
cevice interrogation revealed AT events in approximately
6% of patients (Fig. 2). After initiation of CRT, the
requency and duration of AT episodes significantly de-
reased (p  0.05) (Fig. 3). The average number of AT
pisodes/year was significantly higher and their durations were
ignificantly longer before CRT compared with findings after
pgrade (number/year: pre-CRT, 181  50 vs. post-CRT,
0  20, p  0.05; and duration: pre-CRT, 221  87 s vs.
ost-CRT, 28  21 s, p  0.05). Figure 4 summarizes
ndings with respect to AT frequency on a per-month basis
uring follow-up.
At the 1- and 2-year follow-ups, CRT device interroga-
ion failed to reveal AT episodes in 90% and 86% of
atients, respectively (Fig. 2). There were no differences in
m one patient
intervals are indicated.
aseline Clinical, Demographic,lectrocard ogr phic, and Echocardiographicharacteristics
Table 1
Baseline Clinical, Demographic,
Electrocardiographic, and Echocardiographic
Characteristics
Before CRT After CRT
Age (yrs) 69 9
Male 90%
Female 10%
NICM 24%
ICM 76%
HTN 71%
Hyperlipidemia 81%
DMII 29%
QRS duration (ms) 167 22* 148 13
Echocardiographic parameters
EF % 25.8 5.3* 31.3 7
MR 1.1 0.6 1.2 0.7
LA size (cm) 4.64 0.9 4.98 1
ercentages of comorbid conditions, QRS duration, and echocardiographic data are shown before
nd after cardiac resynchronization therapy (CRT). *Statistically significant difference with p 
.05.
DMII  diabetes mellitus type 2; EF  ejection fraction; HTN  hypertension; ICM  ischemices fro
(V-V)ardiomyopathy; LA  left atrium; MR  mitral regurgitation; NICM  nonischemic
ardiomyopathy.
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September 25, 2007:1246–51 CRT Impact on Atrial Tachyarrhythmiashe mean doses of antiarrhythmic drugs before and after
RT upgrade (Table 2).
ospital stays. Compared with the year before CRT,
ollow-up at 18 to 24 months after CRT revealed a
ignificant reduction in number of total hospital stays as well
s hospital stays deemed to be primarily due to HF or
rrhythmia (Fig. 5A). The number of patients with more
han 1 hospital stay/year (AT-related and total) significantly
ecreased after CRT upgrade, as can be seen in Figures 5B
nd 5C, respectively. Before CRT upgrade there were 9
ospital stays due primarily to atrial fibrillation, 5 hospital
tays associated with atrial flutter or other AT, and 9
ospital stays related to ventricular tachycardia. During the
ollow-up period after CRT upgrade there was 1 atrial
brillation–related hospital stay and 4 hospital stays due to
edications Before and After CRT
Table 2 Medications Before and After CRT
Medications
Before CRT
(Mean Dose in mg/day)
After CRT
(Mean Dose in mg/day)
Metoprolol 86% (120  22) 92% (120  22)
Amiodarone 44% (246  83) 43% (230  67)
Sotalol 11% (240) 14% (240)
Digoxin 43% (0.14  0.06) 38% (0.16  0.08)
ACEI/ARB 76% 81%
Diuretics 71% 71%
Spironolactone 10% 20%
ASA/clopidogrel 95% 95%
Statin 61% 67%
Nitrates 20% 20%
Coumadin 67% 71%
CCB 11% 11%
edications before and after cardiac resynchronization therapy (CRT) “upgrade.” There were no
ignificant differences in prescription frequency or dosing of the main antiarrhythmic medications.
he mean doses/day are shown in parentheses.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; ASA 
cetylsalicylic acid; CCB  calcium channel blocker.
Figure 2 Percentage of Patients Free From
Atrial Tachycardia Over the Course of the Study
Graph illustrating the percentage of patients without atrial tachyarrhythmia over
the course of the study (1 year before and 2 years after cardiac resynchroniza-
tion therapy [CRT]). *Statistically significant difference, p  0.01.entricular tachycardia/fibrillation shocks. The difference in
he number of hospital stays associated with AT before and
fter CRT (14 vs. 1) was statistically significant (p 0.001).
entricular tachycardia/fibrillation-related hospital stays did
ot change significantly. The total number of hospital stays
excluding the hospital stays for the “upgrade”) significantly
ecreased after CRT upgrade (p  0.001).
Figure 3 Atrial Tachycardia Characteristics
Bar graphs depicting mean  SD of frequency (atrial tachycardia episodes/
year), maximum atrial tachycardia duration in minutes, and maximum atrial rate
recorded by the implanted device (in most cases equal to the mode switch
rate) before and after the upgrade to cardiac resynchronization therapy. *Sta-
tistically significant difference, p  0.05.
Figure 4 Frequency of AT Episodes/Month
Bar graphs illustrating mean  SD of the number of atrial tachycardia (AT)
episodes in 1 month recorded at 12 months before cardiac resynchronization
therapy (CRT), 3 months before CRT, and 3 and 12 months after upgrade to
CRT. *Statistically significant difference, p  0.05.
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CRT Impact on Atrial Tachyarrhythmias September 25, 2007:1246–51iscussion
his study examined the impact of CRT on AT suscepti-
ility in patients in whom the presence of pre-existing
Figure 5 Effect of CRT Upgrade on Hospital Stays
(A) Bar graphs summarizing the number of hospital stays in 1 year before and
after the upgrade to cardiac resynchronization therapy (CRT). Findings show
diminished number of atrial tachyarrhythmia (AT) and heart failure (HF) hospital
stays after CRT, whereas other hospital stays (see text) were unaffected. *Sta-
tistically significant difference in the number of hospital stays before and after
CRT (p  0.05). (B and C) Distribution (number of patients) of the number of
hospital stays/year/patient (total and AT-related) before and after CRT
upgrade. p values  0.001 and 0.001, respectively.onventional pulse generators permitted relatively precise nssessment of baseline AT burden. There were 3 principal
bservations. First, in most patients, an upgrade to CRT
ignificantly decreased the number of device-documented
T episodes within the first 3-month observation period
fter the upgrade. Second, the post-CRT decrease in AT
eemed to be progressive over the 2-year prospective obser-
ation period. This finding suggests that the arrhythmia
enefit was not simply due to short-term CRT reversal of
he deteriorating hemodynamic state that had triggered the
CRT upgrade” decision. Finally, CRT upgrade was asso-
iated with a significant decrease in HF and arrhythmia
ospital stays. This observation suggests an important
nteraction between CRT-induced improvement of LV
unction and generation of arrhythmia-related symptoms
eading to hospital admissions. In contrast, and not surpris-
ngly, the frequency of noncardiac hospital stays (e.g.,
rthopedic and noncardiac procedures, general medical
onditions) was unchanged by CRT; this observation tends
o support the validity of the clinical characterization of
ospital admissions used in this study.
mpact of CRT on ATs. Among previously published
tudies assessing the potential impact of CRT on AT
usceptibility in HF patients, excluding case reports (11,12),
he results have been disparate (9,10).
The CARE-HF (Cardiac Resynchronization-Heart Fail-
re) trial provides to date the largest data set in which an
ffort was made to compare the impact of CRT in conjunc-
ion with conventional HF drug therapy versus conventional
harmacological HF treatment alone on frequency of atrial
brillation events (9). The study included more than 800
atients followed for an average of 29 months. Atrial
brillation was detected in 66 CRT-treated patients versus
8 conventional-treatment patients (pNS), suggesting no
pparent CRT benefit. However, because the conventional-
reatment group did not have implanted devices, end point
etection was restricted to adverse event reporting or elec-
rocardiograms recorded during regular follow-up. In es-
ence, it is likely that many AT events were overlooked.
Fung et al. (10) used a case control method to assess atrial
brillation frequency during follow-up in 36 patients receiv-
ng CRT for conventional HF indications. Control subjects
ere matched for age, gender, and LVEF. In this report,
RT patients had a significantly lower atrial fibrillation
ecurrence rate than did control subjects. By 36 months’
ollow-up, 90% of CRT patients were free of atrial
brillation recurrences compared with approximately 70%
n the control group.
The LVEF improvement associated with CRT in our
atient population (26  5.3% to 31  7.0%) was more
losely aligned with observations in the CARE-HF study
9) than with those of Fung et al. (10). Nevertheless, our
T outcomes tend to be more in concordance with Fung
t al. (10). Possibly, the use of each patient as his/her own
ontrol in our study permitted identification of differences
ot detectable by other study designs.
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September 25, 2007:1246–51 CRT Impact on Atrial TachyarrhythmiasDuring the year before CRT upgrade, most of our study
atients had an increasing number of episodes of symptom-
tic and/or asymptomatic (these cannot be distinguished by
ur method) AT episodes as documented by their implanted
ulse generator; 25 of 28 patients had multiple AT episodes
t the last interrogation of the ICD before CRT. In this
egard, it is probable but cannot be determined with
ertainty that the increased arrhythmia frequency was a
yproduct of the hemodynamic deterioration that led to
RT upgrade. A less likely possibility is that more frequent
T episodes led to clinical deterioration. In any case, 3
onths after CRT upgrade, 60% of patients had no re-
orded high-rate atrial episodes. Furthermore, at the 1-year
ost-CRT mark, fully 90% of patients were free from
ecorded AT episodes (a percentage similar to that reported
y Fung et al. [10]).
Possible explanations for a beneficial association between
RT and decrease of atrial fibrillation remain speculative. It
as been argued that many HF-induced structural changes
re often irreversible (13). It seems likely then that structural
hange is only part of the story. A combination of decreased
schemic burden by improvement in cardiac output and
eduction of both atrial and ventricular myocardial wall
tress, in conjunction with a favorable change in neurohu-
oral milieu, could theoretically account for antiarrhythmic
enefit.
tudy limitations. Our study has important limitations.
irst, we identified device-documented high-rate atrial
pisodes. This approach has diagnostic limitations, because
lectrocardiographic evidence is not always available and
ar-field R- or T-wave over-sensing might result in “detec-
ion” of an atrial high rate. Second, our findings are
bservational. We cannot comment on causality in terms of
he apparent beneficial association that has been described.
inally, although this study used a paired analysis with each
atient acting as his/her own control—a design that en-
ances statistical power in small sample populations—it
annot quantify the magnitude of a possible placebo effect
ccompanying an invasive CRT implantation procedure. A
rue randomized control group undergoing a CRT implant
ith the LV stimulation deactivated for a test period would
rovide a stronger study design. However, inasmuch as
ndications for CRT-D upgrade were already well estab-
ished at the start of this study, it was not considered ethical
o insert an inactive device. Ultimately, a multicenter ran-
omized and controlled clinical trial might be needed to
valuate the true impact of CRT on AT susceptibility, and
he latter study design issue will then need to be
e-examined.onclusions
trial tachyarrhythmias are a common occurrence in HF
atients in whom CRT is being contemplated. Further-
ore, the frequency of AT episodes seems to increase in the
onths before CRT implantation. Introduction of CRT
ight lead to both an immediate as well as long-term
ecrease in the number of AT events in a substantial
roportion of HF patients. The mechanism of this associ-
tion needs further investigation.
eprint requests and correspondence: Dr. David G. Benditt,
ail Code 508, 420 Delaware Street, SE, Minneapolis, Minne-
ota, 55455. E-mail: bendi001@umn.edu.
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